Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in HRD-positive metastatic TNBC
NCT05461690Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of niraparib in triple-negative breast cancer (TNBC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
niraparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05461690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05461690.